Drug Trial Radar · NCT05465174
Tovorafenib for Treatment of Craniopharyngioma in Children and Young Adults
Last checked: Nov 19, 2026Latest source record: Apr 23, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
57
Planned (sponsor's estimate)
Start
Sep 12, 2022
Primary completion
Mar 1, 2027
Study completion Mar 1, 2028
Sponsor
- Lead sponsor
- Sabine Mueller, MD, PhDAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- Day One Biopharmaceuticals, Inc.
- First posted
- Jul 19, 2022
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Non randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 1 year, up to 39 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The current study assesses the tolerability and efficacy of monotherapy with pan-RAF-kinase (Tovorafenib) inhibition for the treatment of children and young adults with craniopharyngioma.
Conditions
- Craniopharyngioma, Child
- Craniopharyngioma
- Recurrent Craniopharyngioma
Interventions
TovorafenibDrug
Given orally
Primary outcomes
What the sponsor says the trial is designed to measure.
- Progression free survival rate (PFS)Time frame: Up to 12 months
- Changes in scores on the Physical functioning subscale of the Pediatric Quality of Life Inventory (PedsQL) over timeTime frame: Up to 12 months
Locations
20 sites in 2 countries. Site status is shown where the registry gives one.
University of Alabama at Birmingham
Birmingham, Alabama · Recruiting
Rady Children's Hospital/University of California, San Diego
San Diego, California · Recruiting
University of California, San Francisco
San Francisco, California · Recruiting
University of Florida
Gainesville, Florida · Recruiting
Ann & Robert H. Lurie Children's Hospital of Chicago
Chicago, Illinois · Recruiting
Riley Hospital for Children at Indiana University Health
Indianapolis, Indiana · Recruiting
John Hopkins University
Baltimore, Maryland · Recruiting
Dana-Farber/Boston Children's Harvard Medical School
Boston, Massachusetts · Recruiting
University of Michigan
Ann Arbor, Michigan · Recruiting
Children's Minnesota
Minneapolis, Minnesota · Recruiting
St. Louis Children's Hospital Washington University
St Louis, Missouri · Recruiting
NYU Langone Health
New York, New York · Recruiting
Duke University Medical Center
Durham, North Carolina · Recruiting
Children's Hospital of Philadelphia
Philadelphia, Pennsylvania · Recruiting
University of Utah
Salt Lake City, Utah · Recruiting
John Hunter Children's Hospital
New Lambton Heights, New South Wales, Australia · Recruiting
Royal Hobart Hospital
Hobart, Tasmania, Australia · Recruiting
Children's Cancer Centre, Monash Children's Hospital
Clayton, VIC 3168, Australia · Recruiting
Royal Children's Hospital, Childrens' Cancer Centre
Parkville, Victoria, Australia · Recruiting
Perth Children's Hospital
Nedlands, Western Australia, Australia · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.